Merit Medical Systems, Inc. (MMSI) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $86.14 (-1.01%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 26, 2026 | Larry Biegelsen | Wells Fargo | $78.00 | -9.4% |
| Dec 16, 2025 | David Rescott | Robert W. Baird | $108.00 | +25.4% |
| Oct 31, 2025 | David Rescott | Robert W. Baird | $103.00 | +19.6% |
| Oct 16, 2025 | John Young | Canaccord Genuity | $104.00 | +20.7% |
| May 21, 2025 | John Young | Canaccord Genuity | $112.00 | +30.0% |
| Apr 25, 2025 | Michael Petusky | Barrington | $103.00 | +19.6% |
| Apr 25, 2025 | David Rescott | Robert W. Baird | $110.00 | +27.7% |
| Apr 25, 2025 | Larry Biegelsen | Wells Fargo | $106.00 | +23.1% |
| Oct 15, 2024 | David Rescott | Robert W. Baird | $107.00 | +24.2% |
| Sep 16, 2024 | Mike Matson | Needham | $105.00 | +21.9% |
| Sep 16, 2024 | Larry Biegelsen | Wells Fargo | $103.00 | +19.6% |
| Sep 16, 2024 | Craig Bijou | Bank of America Securities | $103.00 | +19.6% |
| Sep 9, 2024 | Jason Bednar | Piper Sandler | $110.00 | +27.7% |
| Aug 5, 2024 | Craig Bijou | Bank of America Securities | $92.00 | +6.8% |
| Aug 2, 2024 | Jason Bednar | Piper Sandler | $100.00 | +16.1% |
| Jul 2, 2024 | John Young | Canaccord Genuity | $125.00 | +45.1% |
| Jun 13, 2024 | Larry Biegelsen | Wells Fargo | $85.00 | -1.3% |
| May 1, 2024 | Jason Bednar | Piper Sandler | $97.00 | +12.6% |
| Apr 11, 2024 | Kristen Stewart | C.L. King | $88.00 | +2.2% |
| Oct 27, 2023 | Mike Matson | Needham | $81.00 | -6.0% |
Top Analysts Covering MMSI
MMSI vs Sector & Market
| Metric | MMSI | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.19 | 2.25 | 2.42 |
| Analyst Count | 16 | 8 | 18 |
| Target Upside | +17.6% | +16187.2% | +19.5% |
| P/E Ratio | 37.29 | 3.75 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $403M | $408M | $413M | 4 |
| 2026-12-31 | $1.61B | $1.62B | $1.63B | 9 |
| 2027-03-31 | $396M | $401M | $406M | 4 |
| 2027-06-30 | $428M | $434M | $438M | 6 |
| 2027-09-30 | $425M | $430M | $435M | 4 |
| 2027-12-31 | $441M | $447M | $451M | 7 |
| 2028-03-31 | $423M | $429M | $434M | 3 |
| 2028-06-30 | $451M | $457M | $462M | 5 |
| 2028-09-30 | $451M | $457M | $462M | 3 |
| 2028-12-31 | $468M | $475M | $480M | 6 |
| 2029-12-31 | $1.94B | $1.96B | $1.98B | 2 |
| 2030-12-31 | $2.13B | $2.15B | $2.18B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $1.02 | $1.04 | $1.05 | 3 |
| 2026-12-31 | $4.00 | $4.03 | $4.05 | 8 |
| 2027-03-31 | $0.92 | $0.93 | $0.95 | 3 |
| 2027-06-30 | $1.13 | $1.15 | $1.16 | 2 |
| 2027-09-30 | $1.11 | $1.13 | $1.15 | 2 |
| 2027-12-31 | $1.17 | $1.19 | $1.21 | 2 |
| 2028-03-31 | $1.01 | $1.03 | $1.04 | 3 |
| 2028-06-30 | $1.18 | $1.20 | $1.22 | 6 |
| 2028-09-30 | $1.18 | $1.20 | $1.22 | 5 |
| 2028-12-31 | $1.27 | $1.29 | $1.31 | 5 |
| 2029-12-31 | $5.02 | $5.08 | $5.15 | 1 |
| 2030-12-31 | $5.41 | $5.47 | $5.55 | 1 |
Frequently Asked Questions
What is the analyst consensus for MMSI?
The consensus among 16 analysts covering Merit Medical Systems, Inc. (MMSI) is Buy with an average price target of $94.20.
What is the highest price target for MMSI?
The highest price target for MMSI is $125.00, set by John Young at Canaccord Genuity on 2024-07-02.
What is the lowest price target for MMSI?
The lowest price target for MMSI is $78.00, set by Larry Biegelsen at Wells Fargo on 2026-02-26.
How many analysts cover MMSI?
16 analysts have issued ratings for Merit Medical Systems, Inc. in the past 12 months.
Is MMSI a buy or sell right now?
Based on 16 analyst ratings, MMSI has a consensus rating of Buy (2.19/5) with a +17.6% upside to the consensus target of $94.20.
What are the earnings estimates for MMSI?
Analysts estimate MMSI will report EPS of $1.04 for the period ending 2026-09-30, with revenue estimated at $408M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.